Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial.
Initiation of recurrent daily intake of 4 g of acetaminophen in healthy adults is associated with ALT elevations and concomitant treatment with opioids does not seem to increase this effect. Expand
Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans.
A diverse mouse population can be used to understand and predict adverse toxicity in heterogeneous human populations through guided resequencing and it is demonstrated that variation in the orthologous human gene, CD44, is associated with susceptibility to acetaminophen in two independent cohorts. Expand
Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers.
This study shows that the pharmacokinetics of trovafloxacin are linear and stationary and that steady-state serum concentrations above the MICs for most susceptible pathogens attained. Expand
Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users
- S. Harris, Peter J. Perrino, +4 authors E. Sellers
- Journal of clinical pharmacology
- 11 December 2013
Intranasally administered ORF was associated with lower and delayed peak plasma concentrations, decreased drug‐liking, and decreased intranasal tolerability, which suggests that ORF has a decreased potential for intran asal oxycodone abuse. Expand
Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers.
- R. Teng, S. Harris, D. Nix, Jerome J. Schentag, G. Foulds, T. Liston
- The Journal of antimicrobial chemotherapy
Trovafloxacin (CP-99,219) is a new fluoroquinolone antibacterial agent with a broad spectrum of activity against Gram-positive and Gram-negative bacteria and was well tolerated at doses of 300 mg or below. Expand
The Pharmacokinetics and Safety of Single Escalating Oral Doses of Eletriptan
- Ajit K. Shah, S. Harris, C. Greenhalgh, J. Morganroth
- Journal of clinical pharmacology
- 1 May 2002
Oral doses of eletriptan in the therapeutic range were rapidly absorbed and exhibited essentially linear plasma and saliva pharmacokinetics. Expand
Pharmacokinetics, Tolerability, and Safety of Intranasal Administration of Reformulated OxyContin® Tablets Compared with Original OxyContin® Tablets in Healthy Adults
Data suggest that ORF has a lower intranasal abuse potential than OC, and both finely and coarsely crushed ORF retained some control of oxycodone release. Expand
Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover…
The initial rate of absorption was faster, and initial systemic exposure was greater, with ZST compared with oral IR, and systemic exposure of zolpidem was higher in females for both formulations. Expand
Abuse Potential of Intravenous Oxycodone/Naloxone Solution in Nondependent Recreational Drug Users
- S. Colucci, Peter J. Perrino, M. Shram, C. Bartlett, Y. Wang, S. Harris
- Clinical Drug Investigation
- 23 April 2014
Significant reductions in drug liking and other subjective effects following administration of sOXN compared with OXY indicate that naloxone concentrations were sufficient to antagonize the effects of oxycodone when abused by the intravenous route of administration in opioid-experienced drug users. Expand
Oral Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users
HYD demonstrated reduced oral abuse potential compared with hydrocodone solution in healthy adult, nondependent, recreational opioid users and safety was consistent with the known effects of opioid agonists. Expand